Literature DB >> 16239390

Alefacept for psoriasis and psoriatic arthritis.

A B Gottlieb1.   

Abstract

Alefacept is a bioengineered fusion protein of soluble lymphocyte function antigen (LFA-3) with Fc fragments of IgG1. It is marketed in many countries for the treatment of moderate to severe psoriasis. This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16239390      PMCID： PMC1766916          DOI： 10.1136/ard.2005.042655

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  12 in total

1.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

Authors:  C N Ellis; G G Krueger
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

2.  Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells.

Authors:  Joanne C Cooper; Geoffrey Morgan; Susanne Harding; Meena Subramanyam; Gerard R Majeau; Kevin Moulder; Denis R Alexander
Journal:  Eur J Immunol       Date:  2003-03       Impact factor: 5.532

3.  Alefacept in the treatment of psoriatic nail disease: a small case series.

Authors:  Christopher T Cassetty; Andrew F Alexis; Jerome L Shupack; Bruce E Strober
Journal:  J Am Acad Dermatol       Date:  2005-06       Impact factor: 11.527

Review 4.  The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system.

Authors:  T A Springer; M L Dustin; T K Kishimoto; S D Marlin
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

5.  Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.

Authors:  Maarten C Kraan; Arno W R van Kuijk; Huibert J Dinant; Amber Y Goedkoop; Tom J M Smeets; Menno A de Rie; Ben A C Dijkmans; Akshay K Vaishnaw; Jan D Bos; Paul P Tak
Journal:  Arthritis Rheum       Date:  2002-10

6.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Authors:  Gerald G Krueger; Kim A Papp; Dow B Stough; Keith H Loven; Wayne P Gulliver; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

7.  Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

Authors:  Antonio J da Silva; Margot Brickelmaier; Gerard R Majeau; Zhifang Li; Lihe Su; Yen-Ming Hsu; Paula S Hochman
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

8.  Severe psoriasis--oral therapy with a new retinoid.

Authors:  T Fredriksson; U Pettersson
Journal:  Dermatologica       Date:  1978

9.  CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.

Authors:  Alice B Gottlieb; Thomas B Casale; Ellen Frankel; Bernard Goffe; Nicholas Lowe; Hans D Ochs; Janet L Roberts; Ken Washenik; Akshay K Vaishnaw; Kenneth B Gordon
Journal:  J Am Acad Dermatol       Date:  2003-11       Impact factor: 11.527

10.  Remittive effects of intramuscular alefacept in psoriasis.

Authors:  Kenneth B Gordon; Richard G Langley
Journal:  J Drugs Dermatol       Date:  2003-12       Impact factor: 2.114
View more
  1 in total

Review 1.  Adhesion molecules in cutaneous immunity.

Authors:  Robert C Fuhlbrigge; Carsten Weishaupt
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 11.759
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.